Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

Your search for ‘Smart & Biggar’ returned 2,495 results

Use advanced search filters to refine your search

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    2018 Mid-Year Highlights In Canadian Life Sciences IP

    In this special mid-year edition, we take a look at the major highlights in Canadian life sciences and intellectual property law that we have reported on over the last six months ...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Bill C-30 Receives Royal Assent

    As previously reported here, Bill C-30 was passed by the Senate on May 11, 2017. Bill C-30 is the bill that will implement the Canada-European Union Comprehensive Economic and Trade Agreement (CETA).
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
Article

How To Choose And Vet An Expert Witness In Patent Cases

Expert evidence plays a critical role in patent litigation, and can literally make or break a case.
CanadaIntellectual Property
Smart & Biggar
Smart & Biggar
  • Article

    PMPRB Posts Submissions From Guidelines Consultation; Federal Court Challenge Of Amended Regulations Rescheduled

    As previously reported, the Patented Medicine Prices Review Board (PMPRB) extended the consultation period for its draft Guidelines to February 14, 2020. Submissions from the consultation...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Proposed Amendments To Patented Medicines (Pricing) Regulations; SOLIRIS (Pricing, Constitutionality) And DIFFERIN (Jurisdiction) Decisions

    A draft of the new Guidelines is expected in the spring of 2018.
    CanadaIntellectual Property
    Smart & Biggar
    Smart & Biggar
  • Article

    Health Canada Opens Consultation On Draft Guidance Document Distinguishing Between Promotional And Non-Promotional Activities For Health Products

    On July 5, 2019, Health Canada announced a consultation on its new draft guidance: The Distinction Between Promotional and Non-promotional Messages and Activities for Health Products.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Canadian Intellectual Property Office Deadline Extended Until May 1, 2020

    In view of the ongoing COVID-19 pandemic, the Canadian Intellectual Property Office (CIPO) has further extended patent, trademark, and industrial design deadlines fixed under the relevant legislation.
    CanadaCoronavirus (COVID-19)
    Smart & Biggar
    Smart & Biggar
  • Article

    Biosimilars No Longer Reviewed By CADTH

    The Canadian Agency for Drugs and Technologies in Health (CADTH) released Issue 8 of its Pharmaceutical Reviews Update announcing updates
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Health Canada Issues Updated Guidance On PMNOC Regulations

    Health Canada has issued updated guidance reflecting the September 21, 2017 amendments: Guidance Document: Patented Medicines (Notice of Compliance) Regulations (see our summary of the amendments here).
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Comparing Patent Term Extension Regimes Between Canada (CSPs) And The EU (SPCs)

    Amendments to the Patent Act and enactment of the Certificate of Supplementary Protection Regulations flowing from the Canada-European Union Comprehensive Economic and Trade Agreement ...
    CanadaIntellectual Property
    Smart & Biggar
    Smart & Biggar
  • Article

    Ontario Bill 160 Requiring Disclosure Of Financial Relationships Between Pharmaceutical Companies And Health Care Professionals Receives Royal Assent

    The Health Sector Payment Transparency Act, 2017 will come into force on a day to be named by proclamation of the Lieutenant Governor.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Stakeholder Consultation On Naming Of Biologic Drugs, Including Biosimilars

    On January 18, 2018, Health Canada and the Institute for Safe Medication Practices Canada (ISMP Canada) opened its consultation on different approaches to the naming of biologic drugs...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Under Reserve: Appeal From Judicial Review Quashing PMPRB Decision On Jurisdiction Over DIFFERIN

    On January 17, 2019, the Federal Court of Appeal heard the Attorney General of Canada's appeal from a judicial review that quashed a Board decision that it has jurisdiction ...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Apotex Seeks Leave From Supreme Court Of Canada In Cefaclor Damages Action

    As previously reported, the Federal Court of Appeal (FCA) allowed in part Apotex's appeal of a decision awarding Eli Lilly over $100 million for Apotex's infringement ...
    CanadaIntellectual Property
    Smart & Biggar
    Smart & Biggar
  • Article

    Update On PMPRB Guidelines Modernization

    In its April 2019 NEWSletter, the Patented Medicine Prices Review Board (PMPRB) announced that the Steering Committee on Guidelines Modernization would hold its final meeting on May 13, 2019, to discuss both a draft report of its deliberations and the Working Group's final report
    CanadaIntellectual Property
    Smart & Biggar
    Smart & Biggar
  • Article

    Melanie Aitken Steps Down As Commissioner Of Competition

    Melanie Aitken stepped down as Commissioner of Competition on September 21, 2012, a post she held since 2009.
    CanadaAntitrust/Competition Law
    Smart & Biggar
    Smart & Biggar
  • Article

    Certificate Of Supplementary Protection Filing Fee Increase Effective April 1, 2022

    Certificate Of Supplementary Protection Filing Fee Increase Effective April 1, 2022.
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Certificate Of Supplementary Protection Filing Fee Increase Effective April 1, 2023

    On April 1, 2023, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $9,952 to $10,152 in accordance with subsection 9(1)...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Certificate Of Supplementary Protection Filing Fee Increase Effective April 1, 2024

    On April 1, 2024, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $10,152 to $10,356 in accordance with subsection 9(1) of the Certificate...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Article

    Certificates Of Supplementary Protection Filing Fee Increase Effective April 1, 2020

    On April 1, 2020, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $9,376 to $9,564 in accordance with subsection 9(1) of the...
    CanadaFood, Drugs, Healthcare, Life Sciences
    Smart & Biggar
    Smart & Biggar
  • Showing 41–60 of 2495 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics